Michael Zogg joined the Molecular and Systems Toxicology research group in August 2019 for his Master's thesis to investigate species-specific differences in the inhibition of 11β-HSD2. After completing his Master's degree in Drug Sciences in July 2020, he joined the Advanced Therapies & Method development group of Dr. Silvana Libertini at Novartis as an intern for nine months. Michael returned to the Molecular and Systems Toxicology group in July 2021 to start his PhD-Project focusing on the roles of 11β-HSD2 and H6PD in breast cancer cells.